nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2012-405nnp-145Research ArticleArticlesСтатьиClinical experience with requip modutabОпыт применения реквипа модутаба в клинической практикеZakharovDenis ValeryevichZakharovDenis Valeryevichzaharovdv@mail.ruMikhailovV AMikhailovV A-20121409201243NO3 (2012)6062Copyright © Zakharov D.V., Mikhailov V.A., 20122012Zakharov D.V., Mikhailov V.A.Zakharov D.V., Mikhailov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/145

The efficacy of dopamine receptor agonists (DRAs) is determined by a number of advantages. DRAs are recommended as the drugs of choice as monotherapy and in combination with levodopa to enhance the efficiency of therapy for extensive-stage Parkinson’s disease (PD) and to correct motor fluctuations and drug-induced dyskinesias. Controlled-release DRAs are of particular interest. The results of using requip modutab in PD are presented. Its efficacy in treating dyskinesias and fluctuations and the magnitude of side effects are evaluated.

Эффективность агонистов дофаминовых рецепторов (АДР) обусловлена рядом преимуществ. АДР рекомендованы в качестве препаратов выбора в виде монотерапии, а также в комбинации с леводопой с целью усиления эффективности терапии на развернутых стадиях болезни Паркинсона (БП), коррекции моторных флуктуаций и лекарственных дискинезий. Особый интерес представляют АДР с контролируемым высвобождением. Представлены результаты применения реквипа модутаба при БП, оценены его эффективность при дискинезиях и флуктуациях, а также выраженность побочных эффектов.

болезнь Паркинсонаагонисты дофаминовых рецепторовреквип модутабParkinson’s diseasedopamine receptor agonistsrequip modutabReferences<div><p>Артемьев Д.В., Обухова А.В. Современные подходы к лечению ранних стадий болезни Паркинсона. Cons med 2008;10(7):89—92.</p><p>Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Лечение нервных болезней 2003;4(1):14—7.</p><p>Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол журн 1999;4(6):45-9.</p><p>Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. РМЖ 2000;8(15):643-7.</p><p>Adler C.H., Sethi K.D., Hauser R.A. et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson’s disease [published correction appears in Neurology 1997;49:1484]. Neurology 1997;49:393-9.</p><p>Barone P., Bravi D., Bermejo-Pareja F. et al., for the Pergolide Monotherapy Study Group.Pergolide monotherapy in the treatment of early PD. A ramdomized, controlled study. Neurology 1999;53:573-9.</p><p>Brunt E.R., Brooks D.J., Korczyn A.D. et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Pardinson’s disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.</p><p>Clarke C.E., Deane K.H. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2001;1:CD001517.</p><p>Clarke C.E., Speller J.M. Pergolide versus bromocriptine for levodopa-induced motoer complications in Parkinson’s disease. Cochrane Database Syst Rev 2000;2:CD000236.</p><p>Guttman M. for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997;49:1060-5.</p><p>Hely M.A., Morris J.G., Traficante R. et al. The Sydney Multicentre Study of Parkinson’s disease: Progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-7.</p><p>Inzelberg R., Nisipeanu P., Rabey J.M. et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology 1996;47:785-8.</p><p>Leberman A.N., Neophytides A., Leibowitz M. et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson’s disease. Adv Neurol 1983;37:95-108.</p><p>Lieberman A., Olanow C.W., Sethi K. et al., for the Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease [published correction appears in Neurology. 1999;52:435]. Neurology 1998;51:1057-62.</p><p>Montastruc J.L., Rascol O., Senard J.M. et al. A randomised controlled study comparing bromocriptine to whtich levodops was leter added, with Parkinson’s disease: A 5-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.</p><p>Pezzoli G., Martignoni E., Pacchetti C. et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease. Neurology 1995;45(Suppl 3):S22-7.</p><p>Rascol O., Brooks D.J., Dorczyn A.D. et al., for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.</p><p>Rinne U.K. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 1987;37:826-8.</p><p>Rinne U.K., Bracco F., Chouza C. et al., for the PKDS009 Study Group. Early treatment of Parkinson’s disease with cabergoline de;ays the onset of motor complications. Result of a double-bling levodopa controlled trial. Drugs 1998;55(Suppl 1):23-30.</p><p>Thobois S., Delamarre-Damier F., Derkinderen P. Treatment of motor dysfunction in Parkinson’s disease: An overview. Clin Neurol Neurosurg 2005;107:269-81.</p><p>Ziegler M., Castro-Caldas A., Del Signore S. et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: A 6-month, randomized, placebo-controlled study. Mov Dis 2003;18:418-25.</p><p>Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.</p><p>Goetz C.G., Blasucci L., Stebbins G.T. Switching dopamine agonists in advanced Parkinson’s disease: il rapid titration preferable to slow? Neurology 1997;52:1227-9.</p><p>Olanow C.W., Agid Y., Mizuno Y. et al. Levodopa in the treatment of Parkinson’s disease: Current controversies [published correction appears in Mov Dis 2005;20:645]. Mov Dis 2004;19:997-1005.</p><p>Horstink M., Tolosa E., Bonuccelli U. et al. Review of the therapeutic management of Parkinson’s disease. Report of joint task force of EFNS and MDS-ES. Eur J Neurol 2006;13(11):1186—202.</p></div><br /><div><p>Артемьев Д.В., Обухова А.В. Современные подходы к лечению ранних стадий болезни Паркинсона. Cons med 2008;10(7):89—92.</p><p>Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Лечение нервных болезней 2003;4(1):14—7.</p><p>Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол журн 1999;4(6):45-9.</p><p>Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. РМЖ 2000;8(15):643-7.</p><p>Adler C.H., Sethi K.D., Hauser R.A. et al., for the Ropinirole Study Group. Ropinirole for the treatment of early Parkinson’s disease [published correction appears in Neurology 1997;49:1484]. Neurology 1997;49:393-9.</p><p>Barone P., Bravi D., Bermejo-Pareja F. et al., for the Pergolide Monotherapy Study Group.Pergolide monotherapy in the treatment of early PD. A ramdomized, controlled study. Neurology 1999;53:573-9.</p><p>Brunt E.R., Brooks D.J., Korczyn A.D. et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Pardinson’s disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.</p><p>Clarke C.E., Deane K.H. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev 2001;1:CD001517.</p><p>Clarke C.E., Speller J.M. Pergolide versus bromocriptine for levodopa-induced motoer complications in Parkinson’s disease. Cochrane Database Syst Rev 2000;2:CD000236.</p><p>Guttman M. for the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997;49:1060-5.</p><p>Hely M.A., Morris J.G., Traficante R. et al. The Sydney Multicentre Study of Parkinson’s disease: Progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-7.</p><p>Inzelberg R., Nisipeanu P., Rabey J.M. et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology 1996;47:785-8.</p><p>Leberman A.N., Neophytides A., Leibowitz M. et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson’s disease. Adv Neurol 1983;37:95-108.</p><p>Lieberman A., Olanow C.W., Sethi K. et al., for the Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease [published correction appears in Neurology. 1999;52:435]. Neurology 1998;51:1057-62.</p><p>Montastruc J.L., Rascol O., Senard J.M. et al. A randomised controlled study comparing bromocriptine to whtich levodops was leter added, with Parkinson’s disease: A 5-year follow-up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.</p><p>Pezzoli G., Martignoni E., Pacchetti C. et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease. Neurology 1995;45(Suppl 3):S22-7.</p><p>Rascol O., Brooks D.J., Dorczyn A.D. et al., for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.</p><p>Rinne U.K. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: A 5-year follow-up. Neurology 1987;37:826-8.</p><p>Rinne U.K., Bracco F., Chouza C. et al., for the PKDS009 Study Group. Early treatment of Parkinson’s disease with cabergoline de;ays the onset of motor complications. Result of a double-bling levodopa controlled trial. Drugs 1998;55(Suppl 1):23-30.</p><p>Thobois S., Delamarre-Damier F., Derkinderen P. Treatment of motor dysfunction in Parkinson’s disease: An overview. Clin Neurol Neurosurg 2005;107:269-81.</p><p>Ziegler M., Castro-Caldas A., Del Signore S. et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: A 6-month, randomized, placebo-controlled study. Mov Dis 2003;18:418-25.</p><p>Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.</p><p>Goetz C.G., Blasucci L., Stebbins G.T. Switching dopamine agonists in advanced Parkinson’s disease: il rapid titration preferable to slow? Neurology 1997;52:1227-9.</p><p>Olanow C.W., Agid Y., Mizuno Y. et al. Levodopa in the treatment of Parkinson’s disease: Current controversies [published correction appears in Mov Dis 2005;20:645]. Mov Dis 2004;19:997-1005.</p><p>Horstink M., Tolosa E., Bonuccelli U. et al. Review of the therapeutic management of Parkinson’s disease. Report of joint task force of EFNS and MDS-ES. Eur J Neurol 2006;13(11):1186—202.</p></div><br />

The authors declare that there are no conflicts of interest present.